登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《CELL，4月16日，Development of CRISPR as an antiviral strategy to combat SARSCoV-2 and influenza》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-04-16

  • Development of CRISPR as an antiviral strategy to combat SARSCoV-2 and influenza

    Timothy R. Abbott1

    *, Girija Dhamdhere2

    *, Yanxia Liu1

    *, Xueqiu Lin1

    *, Laine Goudy1

    *, Leiping

    SUMMARY

    The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has highlighted the need for

    antiviral approaches that can target emerging viruses with no effective vaccines or

    pharmaceuticals. Here we demonstrate a CRISPR-Cas13-based strategy, PAC-MAN

    (Prophylactic Antiviral CRISPR in huMAN cells), for viral inhibition that can effectively degrade RNA from SARS-CoV-2 sequences and live influenza A virus (IAV) in human lung epithelial cells. We designed and screened CRISPR RNAs (crRNAs) targeting conserved viral regions and identified functional crRNAs targeting SARS-CoV-2. This approach effectively reduced H1N1 IAV load in respiratory epithelial cells. Our bioinformatic analysis showed a group of only six crRNAs can target more than 90% of all coronaviruses. With the development of a safe and effective system for respiratory tract delivery, PAC-MAN has the potential to become an important pan-coronavirus inhibition strategy.

  • 原文来源：https://www.cell.com/pb-assets/products/coronavirus/CELL_CELL-D-20-00736.pdf
28浏览量
原文链接
相关报告

  • 《Cell，4月29日，Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-03
    • The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has highlighted the need for antiviral approaches that can target emerging viruses with no effective vaccines or pharmaceuticals. Here, we demonstrate a CRISPR-Cas13-based strategy, PAC-MAN (prophylactic antiviral CRISPR in human cells), for viral inhibition that can effectively degrade RNA from SARS-CoV-2 sequences and live influenza A virus (IAV) in human lung epithelial cells. We designed and screened CRISPR RNAs (crRNAs) targeting conserved viral regions and identified functional crRNAs targeting SARS-CoV-2. This approach effectively reduced H1N1 IAV load in respiratory epithelial cells. Our bioinformatic analysis showed that a group of only six crRNAs can target more than 90% of all coronaviruses. With the development of a safe and effective system for respiratory tract delivery, PAC-MAN has the potential to become an important pan-coronavirus inhibition strategy.
    44浏览量
    原文链接

  • 《4月15日_CRISPR作为抑制SARSCoV-2和流感的抗病毒策略》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-17
    • 1.时间：2020年4月15日 2.机构或团队：斯坦福大学、DNARx公司、杜克大学等 3.事件概要： 4月15日，Cell期刊在线发表了来自斯坦福大学、DNARx公司、杜克大学等研究团队的题为“Development of CRISPR as an antiviral strategy to combat SARSCoV-2 and influenza”的文章。 该文章报道了一种基于CRISPR-Cas13的抗病毒策略，即PAC-MAN（huMAN细胞中的预防性抗病毒CRISPR），可有效抑制人肺上皮细胞中SARS-CoV-2序列和活性甲型流感病毒（IAV）的RNA降解。该文章指出，研究设计并筛选了靶向保守的病毒区域CRISPR RNA（crRNA），并确定了针对SARS-CoV-2的功能性crRNA。该文章指出，这种方法有效地减少了呼吸道上皮细胞中的H1N1 IAV负荷。该研究报道称，生物信息学分析表明，只有六个crRNA可以靶向90％以上的冠状病毒。该文章认为，PAC-MAN有潜力成为重要的泛冠状病毒抑制策略。 4.附件： 原文链接https://www.cell.com/pb-assets/products/coronavirus/CELL_CELL-D-20-00736.pdf
    67浏览量
    原文链接